Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDPHV-201401 HIV Vaccine Phase 1 Trial in Healthy Adults
NCT04927585Phase 1Completed
- Sponsor
- Worcester HIV Vaccine
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PDPHV-201401 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Worcester HIV Vaccine. Primary endpoints: Frequency of local injection site reactogenicity signs and symptoms at Month 24, Frequency of systemic reactogenicity signs and symptoms at Month 24 and 5 more. Started Jul 2021; status: completed.
02
Drugs
PDPHV-201401
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04927585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927585.